contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


zealand-pharma-conference-call-on-may-8-at-2pm-cet-8am-et-to-present-first-quarter-2025-financial-results

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Zealand Pharma

Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S...

Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark,&nbsp;May 1, 2025&nbsp;–&nbsp;Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. The presentation will be followed by a Q&amp;A session. The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at <a href="https://www.globenewswire.com/Tracker?data=vGq43hvA5MkCiKcK7bdcWS9__r9Q5YLLFOMcgn6NpksBiB3nTbXgrOTX_ET7aqPnm7ilsTMQmp6BcSdE1oJzZblcLrHxCRuXpasIczR1EQJXGE_XV69AngC2nU-Q05g1aBI_FKmpb3nrj3VgG1BT9TIv3DIoDHsGpXh0v2rGURI=">https://edge.media-server.com/mmc/p/tcdv3c9d/</a>. To receive telephone dial-in information and a unique personal access PIN, please register at <a href="https://www.globenewswire.com/Tracker?data=vGq43hvA5MkCiKcK7bdcWdxOPQvRAP97asD0nv5QD8AriareFh-I43VNeoJd2xGHcTnoBxGxsITfvIxDDiZnV-RcVPzxgiTSfZp0QxM0GokINsQqLE-GKu5xZe1hRryreZqWFKStRb21E0zvh-cU0ddRSeFTNNvCbwlMpqempRdSTG-aqBbux6fJ8XGGBpuCCJe4q3U1VyqU0Q7lLmuRCGWEOMYsb0ohsF3WuJ9Cz4HhWwrUnbfKbSD2ZWqXMmuve8KgZSB_eqaYJOHchl-i5g==">https://register-conf.media-server.com/register/BI52c8f77e4cea4195bc9f471f636e1bba</a>. Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investor section of Zealand Pharma’s website at <a href="https://www.globenewswire.com/Tracker?data=vGq43hvA5MkCiKcK7bdcWePnq9LpWA4-cWDZo5yVgi20FxMgkOtvHlkajqXJTP-8ND2_q3hQdNofN3yQd_EFVC8rWHymLEHZkYZBKW16gyZqFnyZrYka-yaYnC_7eWg3f7Qg_XpUxfrsHUWfeCL5gh7AAa2dRQclxtOR7BObaYlj2C499Xnb6g1PvM1GuwAk2TSZrQ7fp5jcMQJ4ItsAsg==">https://www.zealandpharma.com/investors/events-presentations/</a>. About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit <a href="https://www.globenewswire.com/Tracker?data=xkMdGHUtCXlblshgLo7NRmRVKk1Jbq8x29lsqkyayfAvSPUnqlQPCRyKov2XFbx2X_FTFAXnAAvLKDhhUHgT5BVWQk5v6RgnjeL6gO0ig48=">www.zealandpharma.com</a>. Contacts Adam Lange (Investors) Vice President, Investor Relations alange@zealandpharma.com Neshat Ahmadi (Investors) Investor Relations Manager neahmadi@zealandpharma.com Anna Krassowska, PhD (Investor and Media) Vice President, Investor Relations &amp; Corporate Communications akrassowska@zealandpharma.com <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA5Mzk1MCM0MDIxMzM5MjUjMjAwMTcwMQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/MmY2YmVjNWMtMmNhZC00OTBiLWE0NWMtZjEzNzlhOGVmNjM2LTEwMTMyNzQtMjAyNS0wNS0wMS1lbg==/tiny/Zealand-Pharma.png" alt="">

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results